Stay updated with breaking news from Daniel Estban. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter's Transformation (RT), responded to treatment (Objective Response Rate of 100%)1
All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia , with or without Richter’s Transformation , responded to treatment 1 GLPG5201 showed no cytokine... | June 5, 2023
Investegate announcements from Galapagos NV, Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL
All 7 out of 7 eligible patients with relapsed/refractory Chronic Lymphocytic Leukemia, with or without Richter's transformation, responded to treatment (Objective Response Rate of 100%)GLPG5201 showed